louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02788136: Human Chorionic Gonadotropin Stimulation Effects on Steroidogenesis in Men With Klinefelter Syndrome
Official title: Analisi Del Profilo Sierico Steroideo Basale e Dopo Stimolo Con Gonadotropina Corionica Umana (HCG) Nei Soggetti Affetti da Sindrome di Klinefelter (SK).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Steroidogenesis
Klinefelter Syndrome
Human Chorionic Gonadotropin (hCG) Stimulation
Lead sponsor: Azienda USL Modena
Sponsor class: OTHER
First posted: 2016-06-02
Enrollment: 25
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL

Brief summary: The study design included six visits. During the first visit (visit 0), the subjects underwent physical examination(height, weight, body mass index (BMI), arm span, and upper segment measurement) and testicular ultrasound (US) for the calculation of testicular volume. At 0800 h of day 0, all subjects provided a basal blood sample immediately followed by a single intramuscular injection of hCG of 5000 IU. Further five visits were performed each of five following consecutive days after the hCG injection. A blood sample was taken at each visit after an overnight fast

Detailed description: Blood samples were centrifuged at 2955 g for 15 min. Sera were transferred into plain polypropylene tubes and stored at -20°C until assayed. P, 17OHP, AS, DHEA, and TS were determined by LC-MS/MS at the laboratory of the Centre for Applied Biomedical Research of the S. Orsola-Malpighi Hospital, Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Eligibility criteria: Inclusion Criteria:

* Klinefelter syndrome diagnosis at kariotype evaluation for the study group
* Healthy age-matched men in the control group

Exclusion Criteria:

* previous or ongoing androgen therapy

Primary outcomes:
measure: Testosterone
timeFrame: visit 1 (Day 1)
Secondary outcomes:
measure: Testicular volume
timeFrame: visit 0 (Baseline)
measure: Steroids
timeFrame: Visit 0 (Baseline)
measure: Steroids
timeFrame: Visit 1 (Day 1)
measure: Steroids
timeFrame: Visit 2 (Day 2)
measure: Steroids
timeFrame: Visit 3 (Day 3)
measure: Steroids
timeFrame: Visit 4 (Day 4)
measure: Steroids
timeFrame: Visit 5 (Day 5)
Other outcomes:
Locations:
city: Modena
country: Italy
facility: AziendaUSLModena
Study officials:
References:
citation: Belli S, Santi D, Leoni E, Dall'Olio E, Fanelli F, Mezzullo M, Pelusi C, Roli L, Tagliavini S, Trenti T, Granata AR, Pagotto U, Pasquali R, Rochira V, Carani C, Simoni M. Human chorionic gonadotropin stimulation gives evidence of differences in testicular steroidogenesis in Klinefelter syndrome, as assessed by liquid chromatography-tandem mass spectrometry. Eur J Endocrinol. 2016 Jun;174(6):801-11. doi: 10.1530/EJE-15-1224.
Clinical trial NCT03352336: Estimation of Perioperative Atelectasis
Official title: A Comparison Between Two Methods for Estimating the Extent of Perioperative Atelectasis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atelectasis
Oxygenation
Keywords: Atelectasis
Oxygenation
Venous admixture
Computed Tomography
Oxygenation test
Lead sponsor: Region Västmanland
Sponsor class: OTHER
First posted: 2017-11-24
Enrollment: 30
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients fulfilling inclusion and exclusion criteria while attending the day case department of Köping county hospital in Region Västmanland.

Brief summary: This study will compare an oxygenation test based on arterial blood gas analysis with computed tomography for estimating the extent of atelectasis.

Detailed description: Computed tomography of the lungs is the gold standard for investigating the extent of atelectasis, which is common in the perioperative setting. Atelectasis increase the risk of postoperative pulmonary complications and result in pulmonary shunt, which is one of the two major causes of impaired oxygenation. The other cause is admixture of venous blood from poorly ventilated regions of the lungs. The investigators have developed an oxygenation test utilizing arterial blood gas analysis at different inspired fractions of oxygen, which may be used to distinguish between these two causes. This observational study aims to establish the agreement between computed tomography and the oxygenation test for estimating the extent of atelectasis.

Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiology (ASA) class I-II.
* Non-abdominal day case surgery under general anesthesia.
* Patients enrolled in study registered in ClinicalTrials with NCT ID.

Exclusion Criteria:

* Arterial oxygen saturation (SpO2) \<90 % with 40% Venturi mask.
* Unstable postoperative condition needing immediate treatment.

Primary outcomes:
measure: Atelectasis area
timeFrame: 30 min after emergence from anesthesia
Secondary outcomes:
measure: Pulmonary shunt estimated by a standardised oxygenation test
timeFrame: 30 min after emergence from anesthesia
Other outcomes:
Locations:
city: Köping
country: Sweden
facility: Västmanlands sjukhus Köping
state: Västmanland
Study officials:
affiliation: Region Västmanland
name: Lennart Edmark, M.D., Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT05219136: Improve the Comfort, Safety and Quality of Upper Endoscopy by a Modified Fasting Protocol
Official title: Improve the Comfort, Safety and Quality of Upper Endoscopy by a Modified Fasting Protocol：a Double-center, Prospective, Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gastroscopy
Feelings
Fasting
Lead sponsor: Changhai Hospital
Sponsor class: OTHER
Collaborators: name: The Affiliated Traditional Chinese Medicine Hospital Of Southwest Medical University
First posted: 2022-02-01
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This double-center, prospective, interventional study aims to include 200 gastroscopic procedures and investigate the relationship between fasting time and feeling of subjects. The subjects will all receive examination between 10:30 to 11:30am. In the control group, the subjects are required to start the fast at 10:00pm the day before examination and can not drink water after 8:00am on the day of examination. In the test group, the subjects are required to have customized rice congee before 6:30am on the examination day and can not drink water after 8:00am. All subjects complete questionnaire which include discomfort and willingness to accept the same fasting regimen.


Eligibility criteria: Inclusion Criteria:

* No history of benign and malignant tumors (including carcinoma and adenoma) of upper GI (including esophagus, stomach and duodenum)

Exclusion Criteria:

* Subjects that cannot stand the gastroscopy procedure or cannot cooperate with endoscopists
* Emergency endoscopy and therapeutic endoscopy
* Subjects with history of esophageal or stomach surgery or endoscopic surgery
* Pregnant
* Subjects that refuse to cooperate with data collection or sign the informed consent

Primary outcomes:
measure: subject's discomfort
timeFrame: up to 1 week
Secondary outcomes:
measure: incidence of adverse events
timeFrame: up to 1 week
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Changhai Hospital
state: Shanghai
city: Luzhou
country: China
facility: The Affiliated Traditional Chinese Medicine Hospital Of Southwest Medical University
state: Sichuan
Study officials:
affiliation: Changhai Hospital
name: Lei Xin, Dr
role: PRINCIPAL_INVESTIGATOR
affiliation: Changhai Hospital
name: Luo-wei Wang, PhD
role: STUDY_CHAIR
affiliation: The Affiliated Traditional Chinese Medicine Hospital Of Southwest Medical University
name: Li Li, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05499936: 68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)
Official title: Peking Union Medical College Hospital
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: 68Ga-FAPI PET/CT
Metastatic Adenoid Cystic Carcinoma
Keywords: 68Ga-FAPI
PET/CT
Adenoid Cystic Carcinoma
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2022-08-12
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast activating inhibitor, in metastatic adenoid cystic carcinoma（ACC）

Detailed description: 68Ga-FAPI is a positron labeled inhibitor of fibroblast activating protein, which has been widely used in malignant tumor imaging in recent years. Adenoid cystic carcinoma (ACC) is a rare epithelial malignant tumor, which usually originates from salivary glands. Its typical characteristics are long clinical course and high rate of distant metastasis. The purpose of this study was to investigate the clinical value of 68Ga Fapi pet/ct in metastatic adenoid cystic carcinoma.

Eligibility criteria: Inclusion Criteria:

* patients with ACC suspected metastatic tumor,and being able to provide basic information and sign the written informed consent form

Exclusion Criteria:

* claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study

Primary outcomes:
measure: Standardized uptake value of 68Ga-FAPI in ACC
timeFrame: 1 year
Secondary outcomes:
measure: lesions detected by 68Ga-FAPI PET/CT
timeFrame: 1 year
Other outcomes:
measure: compared with 18F-FDG PET/CT or other imaging like CT and MRI
timeFrame: 1 year
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Study officials:
affiliation: Peking Union Medical College Hospital
name: Zhaohui Zhu
role: STUDY_CHAIR
References:
Clinical trial NCT01371136: Developing a Curriculum to Teach Laparoscopic Colorectal Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Education
Simulation
Technical Skills Training
Laparoscopy
Lead sponsor: Unity Health Toronto
Sponsor class: OTHER
Collaborators: name: Canadian Institutes of Health Research (CIHR)
name: Royal College of Physicians and Surgeons of Canada
First posted: 2011-06-10
Enrollment: 25
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: Although a significant amount of work has been done to validate simulators as viable systems to teach technical skills outside the operating room, the next necessary step is to integrate simulator training into a comprehensive curriculum. The purpose of this study is to develop and validate a comprehensive ex-vivo curriculum for laparoscopic colorectal surgery. This curriculum will include training on a virtual reality simulator, cognitive training and cadaver lab training. The investigators will assess the effectiveness of the curriculum by conducting a randomized single blinded controlled trial. The investigators will be comparing the technical performance of curricular trained and non-trained residents in the operating room, during a procedure on a patient. The investigators hypothesize that surgical residents who participate in the curriculum will have superior technical proficiency and cognitive knowledge relating to performing laparoscopic colorectal surgery compared to conventionally trained residents.


Eligibility criteria: Inclusion Criteria:

* resident in general surgery
* post graduate year (PGY) 2 or higher
* performed less than 10 laparoscopic colorectal procedures independently

Primary outcomes:
measure: Difference in operating room performance between intervention and control group
timeFrame: 5 months from intervention
Secondary outcomes:
measure: Difference in cognitive knowledge between intervention and control group
timeFrame: 5 months from the intervention
measure: Difference in technical performance on the virtual reality simulator between intervention and control group residents
timeFrame: 5 months from intervention
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: St. Michael's Hospital
state: Ontario
Study officials:
affiliation: Unity Health Toronto
name: Teodor P Grantcharov, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Palter VN, Grantcharov TP. Development and validation of a comprehensive curriculum to teach an advanced minimally invasive procedure: a randomized controlled trial. Ann Surg. 2012 Jul;256(1):25-32. doi: 10.1097/SLA.0b013e318258f5aa.
Clinical trial NCT06591936: Genetic Profile of Alpha Thalassemia Children at Sohag University Hospital .
Official title: Genetic Profile of Alpha Thalassemia Children at Sohag University Hospital .
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Alpha-Thalassemia
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 50
Sex: ALL
Minimum age (years): 0
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: * Acase suspecteed of alpha thalassemia
* age between 0-18years
* micocytic hypochromic anemia not iron deficiency anemia or Beta thalassemia

Brief summary: Genetic profile of alpha thalassemia children at sohag university hospital ,the aim to determine the prevelance , molecular character of the disorder, characterized by decreased synthesis of alpha -globin Recent work to provide mechanisms for phenotypic heterogeneity .


Eligibility criteria: Inclusion Criteria:

* Acase suspecteed of alpha thalassemia
* age between 0-18years
* micocytic hypochromic anemia not iron deficiency anemia or Beta thalassemia

Exclusion Criteria:

* Age more than 18 years
* healthy children free from any chronic hematological disease
* micocytic hypochromic anemia either iron deficiency anemia or Beta thalassemia

Primary outcomes:
measure: PCR for prevelance of mutation phenotype
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University Hospital
Study officials:
References:
Clinical trial NCT05195736: Predicting COVID-19 Patients' Clinical Outcomes Using ICU Mobility Scale and MRC Sum Score
Official title: Predicting COVID-19 Patients' Barthel Index and Hospitalization Using ICU Mobility Scale and Medical Research Council Sum Score
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Keywords: COVID-19
Activities of Daily Living
Muscle Strength
Lead sponsor: Taichung Veterans General Hospital
Sponsor class: OTHER
First posted: 2022-01-19
Enrollment: 33
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: COVID-19 patients admitted at Taichung VGH from 2020/1/1 to 2021/6/15

Brief summary: The investigators hypothesize that early mobility condition and muscle power may be the predictive factors for Coronavirus disease 2019(COVID-19) patients' activity prognosis and hospitalization days. To prove our hypothesis, the investigators proposed a retrospective cohort study to see if ICU mobility scale(ICUMS) and Medical Research Council Sum Score(MRCSS) can predicted the patients' Barthel index after discharge and hospitalization days.

Detailed description: The investigators hypothesize that early mobility condition and muscle power may be the predictive factors for COVID-19 patients' activity prognosis and hospitalization days. To prove our hypothesis, the investigators checked the patient's baseline ICUMS and MRCSS upon admission. Also, blood test results were also obtained. Subsequently, the investigators measured their outcomes by Barthel index and hospitalization length, and divided them into two groups. The ICUMS, MRCSS and the blood test results differences between two groups were checked. For those factors that showed significant difference between two groups, the investigators recruited them into regression model. Last, receiver operating curve of those factors were plotted to find the appropriate cutoff points for identifying two groups of outcomes.

Eligibility criteria: Inclusion Criteria:

* COVID-19 patients diagnosed by positive polymerase chain reaction(PCR)

Exclusion Criteria:

* Impaired baseline activities, such as stroke, fracture, neurodegenerative disease
* Baseline Barthel index score less than 100
* Lost follow-up

Primary outcomes:
measure: Barthel index
timeFrame: Barthel index score 3 months after discharge
measure: Hospitalization days
timeFrame: days
Secondary outcomes:
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital
state: Republic Of China(R.O.C)
Study officials:
References:
Clinical trial NCT02405936: Prospective Data Collection of Patients Undergoing Gynecologic Surgery
Official title: Prospective Data Collection of Patients Undergoing Gynecologic Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Disease (or Disorder); Gynecological
Lead sponsor: Kangbuk Samsung Hospital
Sponsor class: OTHER
First posted: 2015-04-01
Enrollment: 3000
Sex: FEMALE
Minimum age (years): 16
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015

Brief summary: The aim of this prospective study is to collect data on patients undergoing gynecologic surgery at Kangbuk Samsung Hospital.

Detailed description: The aim of this prospective study is to collect data on patients undergoing gynecologic surgery at Kangbuk Samsung Hospital. If patients agree to participate in this clinical trial, patient's data (such as age, body mass index, preoperative findings, laboratory findings, radiologic findings, operative findings, pathologic findings, postoperative findings) will be collected in a research database. The research database will be updated, every 6 month, to include data on patient's disease outcome and follow-up care. Although most data will be collected form the medical record, patient may agin be contacted so that researchers can collection some data if it is not in the medical record.

Eligibility criteria: Inclusion Criteria:

* All patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015

Exclusion Criteria:

* None

Primary outcomes:
measure: Prospective data collection of patients undergoing gynecologic surgery
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Kangbuk Samsung Hospital
Study officials:
affiliation: Kangbuk Samsung Hospital, Seoul, Republic of Korea
name: Taejong Song, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01157936: Hyperuricemia on Hypertension and Metabolic Syndrome
Official title: Effect of Hyperuricemia Treatment on Hypertension and Metabolic Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Systolic and Diastolic Blood Pressure Levels
Uric Acid Levels
Metabolic Syndrome Parameters
Hepatic Enzymes
Keywords: hypertension
hyperuricemia
metabolic syndrome
Lead sponsor: Instituto Nacional de Cardiologia Ignacio Chavez
Sponsor class: OTHER
Collaborators: name: National Council of Science and Technology, Mexico
First posted: 2010-07-08
Enrollment: 40
Sex: ALL
Minimum age (years): 25
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the influence of hyperuricemia treatment compared with placebo on participants with high risk of hypertension and metabolic syndrome.

Detailed description: Elevated consumption of high fructose corn syrup has lead to an increase of 30% of fructose intake since the last 20 years. Important data supporting this fact can be reflected on incidence and prevalence of Metabolic syndrome and hyperuricemia.

A peculiar effect of fructose intake demonstrated in animal models is the development of elevated uric acid levels; also some studies have found a clear association between hyperuricemia as an important risk factor for hypertension, diabetes mellitus, chronic kidney disease and metabolic syndrome.

Taking into account the existing evidence, our clinical research team presents this protocol as a way to evaluate the effect of uric acid treatment and its relation with Fructose consumption, metabolic syndrome parameters, hyperuricemia and risk of hypertension.

Confirming evidence with clinical basis may be the initial strategy to create primary prevention programs to control this health problems affecting Mexican Population.

Eligibility criteria: Inclusion Criteria:

* adults with blood pressure from 120/80 mmHg and less than 140/90 mmHg
* no pharmacological treatment for blood pressure control

Exclusion Criteria:

* hypertension (more than 140/90mmHg)
* Diabetes Mellitus type 1 or 2
* Chronic kidney disease (MDRD less than 60)
* Hepatic Disease
* Malignancy
* Pregnancy
* patient receiving any medication

Primary outcomes:
measure: Effect of hyperuricemia treatment on systemic blood pressure
timeFrame: 14 weeks
Secondary outcomes:
measure: Effect of hyperuricemia treatment on metabolic syndrome parameters
timeFrame: 14 weeks
Other outcomes:
Locations:
city: Mexico
country: Mexico
facility: Insituto Nacional de Cardiología Ignacio Chávez
Study officials:
affiliation: Instituto Nacional de Cardiología Ignacio Chávez
name: Magdalena Madero, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Fravel MA, Ernst ME. Management of gout in the older adult. Am J Geriatr Pharmacother. 2011 Oct;9(5):271-85. doi: 10.1016/j.amjopharm.2011.07.004. Epub 2011 Aug 17.